Ammonul

Ammonul is a brand name of sodium benzoate/sodium phenylacetate, approved by the FDA in the following formulation(s):

AMMONUL (sodium benzoate; sodium phenylacetate - solution; iv (infusion))

• 
  Manufacturer: UCYCLYD
  
  Approval date: February 17, 2005
  
  Strength(s): 10%;10% (5GM/50ML;5GM/50ML) ^[RLD]

Has a generic version of Ammonul been approved?

No. There is currently no therapeutically equivalent version of Ammonul available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ammonul. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ammonul.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 17, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Ammonul Consumer Information (Drugs.com)
• Ucephan Advanced Consumer Information (Micromedex)
• Sodium benzoate and sodium phenylacetate Advanced Consumer Information (Micromedex)
• Sodium Phenylacetate and Sodium Benzoate AHFS DI Monographs (ASHP)